IDENTITY FILE 03 / GHRH ANALOGUE
Tesamorelin: Research Overview
A population-specific evidence record for a GHRH analogue studied chiefly in HIV-associated abdominal fat accumulation.
The short version
Tesamorelin is a synthetic version of growth-hormone-releasing hormone. It prompts the pituitary gland to release the body’s own growth hormone, which then raises IGF-1 and affects fat metabolism. Its best-supported clinical use is narrow: reducing excess abdominal fat in adults with HIV-associated lipodystrophy, a condition in which fat distribution changes in the setting of HIV treatment. It is not a general-purpose weight-loss finding.
Randomized trials and a pooled analysis report reductions in visceral fat—the fat around internal organs—and hepatic fat in this specific population [13][15][17]. A study in healthy men helps explain the hormone mechanism but does not establish a body-composition benefit for the general population [16]. Unlike CJC-1295, tesamorelin is an approved prescription medicine for a defined indication. Like CJC-1295, it acts through the GHRH receptor. The shared pathway makes comparison useful, but it does not make the compounds interchangeable. Identity, population, duration, and approved context all remain part of the evidence record.
What it is
Tesamorelin acetate contains a synthetic 44-amino-acid analogue of human GHRH with an N-terminal modification that improves resistance to enzymatic cleavage. Development code TH9507, the chemical description trans-3-hexenoyl-GHRH(1-44) amide, and the nonproprietary name tesamorelin belong in the same compound record. The acetate designation identifies the supplied salt rather than a separate therapeutic mechanism.
The United States approved tesamorelin in 2010 for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [14]. That wording is an evidence boundary. Trials in this collection largely concern adults living with HIV and receiving antiretroviral therapy. Extending those results to general obesity, healthy aging, or non-HIV liver disease would require separate evidence. The compound’s clinical status is more mature than CJC-1295’s, but its indication is much narrower than the broad “fat loss peptide” label often used in informal discussion.
How it works
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotroph cells. Signaling through adenylyl cyclase, cyclic AMP, and protein kinase A stimulates synthesis and pulsatile secretion of endogenous growth hormone. Growth hormone then promotes hepatic IGF-1 production and contributes to lipolysis, with the clinical program focusing on visceral adipose tissue.
A study in 13 healthy men measured the mechanism directly. After two weeks of studied exposure, mean overnight growth hormone increased by 0.5 micrograms per liter and IGF-1 increased by 181 micrograms per liter; fasting glucose and insulin-stimulated glucose uptake did not change significantly in that short experiment [16]. The small sample and short duration make this a mechanistic study, not a general safety verdict. It supports the pathway description while leaving longer-term and population-specific questions to larger trials.
What the research shows
A 2026 meta-analysis pooled five randomized controlled trials in HIV-associated lipodystrophy. Tesamorelin reduced visceral adipose area by a mean 27.71 square centimeters, trunk fat by 1.18 kilograms, and hepatic fat fraction by 4.28 percentage points, while lean body mass increased by 1.42 kilograms; each pooled result was statistically significant [13]. The analysis reported no serious adverse events, but pooled trial safety does not eliminate longer-term or individual clinical considerations [13].
In a six-month randomized trial of 50 antiretroviral-treated adults with HIV, tesamorelin produced a 42-square-centimeter treatment effect in visceral fat and a net 2.9-percentage-point reduction in hepatic fat relative to placebo [15]. In a longer program, visceral fat was 18% below baseline after 52 weeks, but it reaccumulated after discontinuation; glucose changes over that period were not clinically significant [17]. The consistent signal concerns visceral fat in HIV-associated abdominal fat accumulation. It should not be rewritten as undifferentiated total weight loss.
Reported effects, cautions & safety
This composed record contains no community-signal set for tesamorelin, so this desk does not manufacture one. Statements circulating in user communities would be anecdotal, not clinical evidence, but none are summarized here without a supplied record. The clinical findings instead emphasize changes in visceral fat, hepatic fat, lean mass, and GH/IGF-1 signaling in defined study populations [13][15][16][17].
The principal interpretive caution is scope. Approval is limited to excess abdominal fat in adults with HIV-associated lipodystrophy [14]. Visceral fat reaccumulated after treatment stopped in the longer study, showing that the measured effect was not a permanent reset [17]. GH-axis stimulation raises IGF-1, so active malignancy, glucose regulation, and other pathway-related issues belong in clinical assessment even though this page gives no individual guidance. The NIH LiverTox monograph rated tesamorelin an unlikely cause of clinically apparent liver injury and reported no attributable cases in its review [14]. That finding addresses liver injury; it is not a blanket safety endorsement.
Where it fits in Research Peptide Fundamentals
Tesamorelin is the collection’s clearest example of population boundaries. The molecule has an approved use and randomized evidence, yet the most defensible summary remains narrow: visceral-fat reduction in HIV-associated lipodystrophy. Replacing that phrase with “belly-fat peptide” removes the population, the clinical condition, and the actual endpoint.
Its relation to CJC-1295 also illustrates why pathway is not identity. Both are GHRH analogues, and both stimulate endogenous GH/IGF-1 signaling [1][16]. Their structures, durations, development histories, regulatory positions, and clinical datasets differ. Semaglutide reaches body weight through GLP-1 receptor pharmacology, while PT-141 acts centrally through melanocortin receptors. A careful digest groups tesamorelin with CJC-1295 for mechanism comparison but does not pool their outcomes.